Wanbury Limited (BOM:524212)
243.00
-10.00 (-3.95%)
At close: Mar 4, 2026
Wanbury Revenue
Wanbury had revenue of 1.62B INR in the quarter ending December 31, 2025, with 21.73% growth. This brings the company's revenue in the last twelve months to 6.58B, up 16.13% year-over-year. In the fiscal year ending March 31, 2025, Wanbury had annual revenue of 6.00B with 3.88% growth.
Revenue (ttm)
6.58B
Revenue Growth
+16.13%
P/S Ratio
1.32
Revenue / Employee
4.76M
Employees
1,382
Market Cap
8.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.00B | 224.42M | 3.88% |
| Mar 31, 2024 | 5.78B | 780.91M | 15.63% |
| Mar 31, 2023 | 5.00B | -115.39M | -2.26% |
| Mar 31, 2022 | 5.11B | 1.19B | 30.23% |
| Mar 31, 2021 | 3.93B | 250.63M | 6.82% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TTK Healthcare | 8.30B |
| Anuh Pharma | 7.68B |
| Venus Remedies | 7.03B |
| Lincoln Pharmaceuticals | 6.52B |
| Sudarshan Pharma Industries | 6.44B |
| Kopran | 6.20B |
| Fredun Pharmaceuticals | 5.91B |
| Fermenta Biotech | 5.44B |
Wanbury News
- 5 weeks ago - Wanbury begins commercial production of high-potent anaesthetic API - Business Upturn
- 5 months ago - Wanbury implements SAP S/4HANA ERP to drive future ready operations - Business Upturn
- 8 months ago - Wanbury launches next-gen iron supplement ‘C RED’ to revolutionize anemia management in India - Business Upturn
- 10 months ago - Wanbury receives GMP certification from ANVISA for Patalganga facility - Business Upturn
- 10 months ago - Wanbury’s Tanuku facility in Andhra Pradesh completes ANVISA inspection with zero observations - Business Upturn
- 1 year ago - Wanbury launches Wanbury C-RED and Ketamine Hydrochloride - Business Upturn
- 1 year ago - Wanbury shares rise 2.56% following company refinances Rs 95 crore NCDs, reducing interest costs - Business Upturn
- 1 year ago - Wanbury secures lower-cost refinancing for outstanding debentures - Business Upturn